Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.

NCT06955910 · Istituto Oncologico Veneto IRCCS · Updated 16 July 2026

What is being tested
questionnaires
For
Prostate Cancer; Bladder Cancer; Kidney Cancer
Kind of study
Watches patients without assigning a treatment. No drug phase (a device or procedure study).
Who can join
Ages 18 years to 99 years. About 120 people. The full rules are on the registry page.
Where
Italy
When
Starts or started 18 June 2025, ends 13 April 2026. Registered 2 May 2025.
Results
None posted yet.

In the researchers' words

Patients previously treated with robotic surgery for urological cancers such as prostate, bladder and kidney cancer will be enrolled, in particular patients operated in the last twelve months will be included after signing the informed consent. Within 12 months after mini-invasive procedure, subjects are identified, contacted by phone/email, or invited to attend during the regular scheduled follow-up visit. If this is not possible, patients will be asked to schedule a special interview to assess possible participation in the study. During follow-up or unscheduled visit, the subsequent information will be collected through a questionnaire that contains several socio-demographic and anamnestic questions. During subsequent visit, PROFFIT and EORTC QLQ-C30 questionnaires will be administered to patients. Post-operative complications are reported using the Clavien-Dindo classification. Anamnestic and socio-demographic information will be collected through a generic self-designed questionnaire including the following data: age, sex, residence (within or outside the Veneto region), marital status (married, divorced, cohabiting, single, widowed), employment status (employed, unemployed, retired), presence of dependents (yes/no), level of education (defined as primary, middle or high school, university degree), concomitant pathologies. Additional data on the oncological history are…
ClinicalTrials.gov, NCT06955910

Sites

  • Istituto Oncologico VenetoPadova, Italy/Padova, Italy